10 February 2014 - Skyepharma, the expert oral and inhalation drug delivery company, announces that, following regulatory approval and agreement on pricing reimbursement, flutiform has now been launched in France. Mundipharma will market flutiform® in France in 50/5 µg and 125/5 µg strengths for the treatment of asthma.  Skyepharma will receive a milestone of €3.0 million (£2.5 million at current exchange rates) and royalties on net sales.

For more details, go to: http://online.hemscottir.com/ir/skp/ir.jsp?page=news-item&item=1690514160091136